Literature DB >> 19798582

Fracture risk assessment in postmenopausal women.

Ronald C Hamdy1.   

Abstract

Patients with osteoporosis have an increased risk of sustaining fractures because of the low bone mineral density (BMD) and altered bone micro-architecture which are characteristic features of the disease. Although a good correlation exists between BMD and fracture risks, many other factors influence this relationship. While there is consensus that patients with osteoporosis should be investigated and treated, the issue is much less clear for patients with osteopenia. Because osteopenia is so prevalent, it would be unrealistic to treat all patients with this condition. Therefore, there is a need to identify those patients who are at risk of sustaining a fracture and would benefit most from the available therapy. Providing treatment to the appropriate risk group would not only reduce the number of fractures, but could also reduce the adverse effects associated with treatment, as treating patients earlier could shorten the treatment time. The availability of tools to select patients at risk of fracture should change the impact of the disease.

Entities:  

Mesh:

Year:  2010        PMID: 19798582     DOI: 10.1007/s11154-009-9118-4

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  56 in total

Review 1.  Bone matters: are density increases necessary to reduce fracture risk?

Authors:  K G Faulkner
Journal:  J Bone Miner Res       Date:  2000-02       Impact factor: 6.741

2.  Pathophysiology of bone loss in patients receiving anticonvulsant therapy.

Authors:  Lorraine A Fitzpatrick
Journal:  Epilepsy Behav       Date:  2004-02       Impact factor: 2.937

3.  Selecting patients for osteoporosis therapy.

Authors:  Stuart Silverman
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

4.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

5.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

6.  The management of osteoporosis following hip fracture: have we improved our care?

Authors:  Sachin Bahl; Penelope S Coates; Susan L Greenspan
Journal:  Osteoporos Int       Date:  2003-10-16       Impact factor: 4.507

7.  Fractures as predictors of excess mortality in the aged-a population-based study with a 12-year follow-up.

Authors:  Maarit Piirtola; Tero Vahlberg; Minna Löppönen; Ismo Räihä; Raimo Isoaho; Sirkka-Liisa Kivelä
Journal:  Eur J Epidemiol       Date:  2008-10-01       Impact factor: 8.082

8.  A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies.

Authors:  Saskia M F Pluijm; Bart Koes; Chris de Laet; Natasja M Van Schoor; Natalia O Kuchuk; Fernando Rivadeneira; Johan P Mackenbach; Paul Lips; Huibert A Pols; Ewout W Steyerberg
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

9.  Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents.

Authors:  K W Lyles; A P Schenck; C S Colón-Emeric
Journal:  Osteoporos Int       Date:  2008-02-27       Impact factor: 4.507

10.  A simple clinical score for estimating the long-term risk of fracture in post-menopausal women.

Authors:  T P van Staa; P Geusens; J A Kanis; H G M Leufkens; S Gehlbach; C Cooper
Journal:  QJM       Date:  2006-09-23
View more
  5 in total

1.  Effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cell proliferation, differentiation and OPG/RANKL mRNA expression.

Authors:  Yan Ren; Shu-Yan Han; Ping-Ping Li
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

2.  Efficacy of proline in the treatment of menopause.

Authors:  Sun-Young Nam; Myoung-Schook Yoou; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-31

3.  Contralateral hip fractures and other osteoporosis-related fractures in hip fracture patients: incidence and risk factors. An observational cohort study of 1,229 patients.

Authors:  Anne J H Vochteloo; Boudewijn L S Borger van der Burg; Maarten A Röling; Diederik H van Leeuwen; Peter van den Berg; Arthur H P Niggebrugge; Mark R de Vries; Wim E Tuinebreijer; Rolf M Bloem; Rob G H H Nelissen; Peter Pilot
Journal:  Arch Orthop Trauma Surg       Date:  2012-04-24       Impact factor: 3.067

4.  Risk factors for hip fracture in New Zealand older adults seeking home care services: a national population cross-sectional study.

Authors:  Rebecca Abey-Nesbit; Philip J Schluter; Tim Wilkinson; John Hugh Thwaites; Sarah D Berry; Hamish A Jamieson
Journal:  BMC Geriatr       Date:  2019-03-25       Impact factor: 3.921

5.  Morbidity and Mortality After Second Hip Fracture With and Without Nursing Care Program.

Authors:  Konstantina Solou; Minos Tyllianakis; Antonis Kouzelis; John Lakoumentas; Andreas Panagopoulos
Journal:  Cureus       Date:  2022-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.